Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
Stopped early · Phase 1/Phase 2
Conditions studied: Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Pancreatic Cancer, Biliary Tract Cancer, Cholangiocarcinoma, Metastatic Cancer
In brief
This study was planned as an open-label, multi-site, Phase I/IIa dose escalation, safety, and pharmacokinetic (PK) trial of BNT141 followed by expansion cohorts in patients with Claudin 18.2 (CLDN18.2)-positive tumors. The sponsor decided to stop the development of BNT141 on 24 July 2023 and the study was terminated early.
Key facts
- Study ID
- NCT04683939
- Run by
- BioNTech SE
- People needed
- 13
- Starts
- 2022-01-18
- Expected to finish
- 2023-07-24
- Last updated by the study team
- 2024-10-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- City of Hope — Duarte, California, United States
- MD Anderson Cancer Center — Houston, Texas, United States
- NEXT Oncology — San Antonio, Texas, United States
- START — San Antonio, Texas, United States
- University of Montreal - Centre Hospitalier de l´Université de Montréal — Montreal, Canada
- St. Michaels Hospital — Toronto, Canada
- Princess Margaret Cancer Centre - University Health Network — Toronto, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.